New Antisense Drug Safely Reduces Parkinson's Disease Protein by 59% in First Human Trial
Experimental BIIB094 treatment lowered harmful LRRK2 protein levels in spinal fluid, offering hope for genetic Parkinson's patients.
Summary
A groundbreaking phase 1 trial tested BIIB094, an antisense drug that targets genetic forms of Parkinson's disease. The treatment safely reduced levels of LRRK2, a protein linked to the most common genetic cause of Parkinson's, by up to 59% in patients' spinal fluid. Eighty-two participants received either single or multiple doses of the drug injected directly into the spine. The treatment was well-tolerated with mostly mild side effects and no serious drug-related adverse events. The drug also reduced related inflammatory markers, suggesting it may address underlying disease mechanisms rather than just symptoms.
Detailed Summary
LRRK2 gene variants cause the most common inherited form of Parkinson's disease, making this protein an attractive target for disease-modifying treatments. Unlike current therapies that only manage symptoms, targeting LRRK2 could potentially slow or halt disease progression.
Researchers conducted the first human trial of BIIB094, an antisense oligonucleotide that degrades LRRK2 messenger RNA. The REASON study enrolled 82 Parkinson's patients across two phases. Part A tested single doses in 40 participants, while Part B gave 42 patients four monthly treatments.
The drug demonstrated impressive biological activity, reducing cerebrospinal fluid LRRK2 levels by up to 59% and related phosphorylated Rab10 protein by 50%. These reductions occurred regardless of whether patients carried LRRK2 mutations. The treatment also decreased lysosomal proteins, suggesting it may address cellular cleanup mechanisms disrupted in Parkinson's disease.
Safety results were encouraging, with adverse events reported in 65% of single-dose and 85% of multiple-dose participants. Most side effects were mild to moderate, and no serious drug-related events occurred. The drug's concentration increased predictably with higher doses.
For longevity and health optimization, this represents a paradigm shift toward precision medicine for neurodegenerative diseases. Rather than managing symptoms after significant brain damage occurs, antisense therapies could preserve neuronal function by targeting disease roots. However, this early-stage trial focused on safety and biological markers rather than clinical improvements, so efficacy remains unproven.
Key Findings
- BIIB094 safely reduced disease-causing LRRK2 protein levels by up to 59% in patient spinal fluid
- Treatment lowered inflammatory markers suggesting impact on underlying Parkinson's mechanisms
- No serious drug-related side effects occurred across 82 participants in phase 1 trial
- Drug effects occurred in both genetic and non-genetic Parkinson's patients
- Monthly spinal injections showed dose-dependent protein reduction over 16 weeks
Methodology
Randomized, placebo-controlled phase 1 trial with 82 Parkinson's patients. Part A tested single intrathecal doses (10-150mg), Part B tested four monthly doses (40-120mg). Primary endpoints were safety and cerebrospinal fluid biomarker changes.
Study Limitations
Phase 1 trial focused on safety rather than clinical efficacy. Long-term effects unknown, and spinal injection delivery method may limit practical application. Larger trials needed to demonstrate actual symptom improvement.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.